IFN-β, the first DMT used for MS-treatment, decreases the number of circulating neutrophils in RRMS patients, further supported by a decrease in neutrophil infiltration in animal models, probably by downregulation of CXCR2 ligands [162,163]. The gene discussed is CXCR2; the disease is myeloid sarcoma.